TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares

2026-03-04 18:32:14 ET Takeda Pharmaceutical Company Limited (TAK) TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM EST... Read the full article on Seeking Alpha For further details see: Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th A...

2026-03-04 12:48:38 ET More on Takeda Pharmaceutical Takeda Tests New Highs, But Struggles To Find Entyvio Successor Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P...

Alan Walshe Appointed General Manager of Takeda Canada Canada NewsWire A proven people ‑ focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact. TORONTO , March 2, 2026  /CNW/ -  Takeda Canada...

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Dou...

2026-02-26 14:04:32 ET The last time I spoke about Ironwood Pharmaceuticals ( IRWD ), it was with respect to a Seeking Alpha article entitled " Ironwood Pharmaceuticals: Q3 of 2024 Data Readout For PBC ." With respect to this article, I mentioned a huge opportunity that the ...

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Canada NewsWire Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts Market News Updates News Commentary NEW YORK , Feb. 24, 202...

2026-02-20 09:24:40 ET More on Novo Nordisk Novo Nordisk Is Under Pressure - And Trading At A Discount Novo Nordisk: The Possible Upside Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk board proposes DKK 7.95 final dividend for ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of...

2026-02-11 10:00:00 ET It takes all the running you can do to keep in the same place. If you want to get somewhere else, you must run at least twice as fast! —Through the Looking-Glass (Lewis Carroll) Looking Back About 1.5 years ago, I opened a Long p...

2026-02-10 08:30:33 ET Improved efficacy, faster onset, and scalable platforms drive investor interest in next-gen CNS assets New York, NY –February 10, 2026 – Market News Updates News Commentary – Novel serotonergic agonists (“NSAs”...